FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4211130145> ?p ?o ?g. }

• W4211130145 endingPage "429" @default.
• W4211130145 startingPage "421" @default.
• W4211130145 abstract "International guidelines recommend supervised exercise therapy (SET) as primary treatment for all patients with intermittent claudication (IC), yet primary endovascular revascularisation (ER) might be more effective in patients with iliac artery obstruction.This was a multicentre RCT including patients with IC caused by iliac artery stenosis or occlusion (NCT01385774). Patients were allocated randomly to SET or ER stratified for maximum walking distance (MWD) and concomitant SFA disease. Primary endpoints were MWD on a treadmill (3.2 km/h, 10% incline) and disease specific quality of life (VascuQol) after one year. Additional interventions during a mean follow up of 5.5 years were recorded.Between November 2010 and May 2015, 114 patients were allocated to SET, and 126 to ER. The trial was terminated prematurely after 240 patients were included. Compliance with SET was 57/114 (50%) after six months. Ten patients allocated to ER (8%) did not receive this intervention. One year follow up was complete for 90/114 (79%) SET patients and for 104/126 (83%) ER patients. The mean MWD improved from 187 to 561 m in SET patients and from 196 to 574 m in ER patients (p = .69). VascuQol sumscore improved from 4.24 to 5.58 in SET patients, and from 4.28 to 5.88 in ER patients (p = .048). Some 33/114 (29%) SET patients had an ER within one year, and 2/114 (2%) surgical revascularisation (SR). Some 10/126 (8%) ER patients had additional ER within one year and 10/126 (8%) SR. After a mean of 5.5 years, 49% of SET patients and 27% of ER patients underwent an additional intervention for IC.Taking into account the many limitations of the SUPER study, both a strategy of primary SET and primary ER improve MWD on a treadmill and disease specific Qol of patients with IC caused by an iliac artery obstruction. It seems reasonable to start with SET in these patients and accept a 30% failure rate, which, of course, must be discussed with the patient. Patients continue to have interventions beyond one year." @default.
• W4211130145 created "2022-02-13" @default.
• W4211130145 creator A5000135344 @default.
• W4211130145 creator A5000971547 @default.
• W4211130145 creator A5001132734 @default.
• W4211130145 creator A5002980382 @default.
• W4211130145 creator A5003110546 @default.
• W4211130145 creator A5003262828 @default.
• W4211130145 creator A5003767745 @default.
• W4211130145 creator A5004594976 @default.
• W4211130145 creator A5007353286 @default.
• W4211130145 creator A5007806747 @default.
• W4211130145 creator A5009966256 @default.
• W4211130145 creator A5011753092 @default.
• W4211130145 creator A5012208235 @default.
• W4211130145 creator A5013219969 @default.
• W4211130145 creator A5014704531 @default.
• W4211130145 creator A5015525811 @default.
• W4211130145 creator A5016789255 @default.
• W4211130145 creator A5017957176 @default.
• W4211130145 creator A5018434621 @default.
• W4211130145 creator A5020399597 @default.
• W4211130145 creator A5020559426 @default.
• W4211130145 creator A5021579882 @default.
• W4211130145 creator A5021753521 @default.
• W4211130145 creator A5021808272 @default.
• W4211130145 creator A5022369090 @default.
• W4211130145 creator A5024133489 @default.
• W4211130145 creator A5026697149 @default.
• W4211130145 creator A5027431967 @default.
• W4211130145 creator A5027974936 @default.
• W4211130145 creator A5028254994 @default.
• W4211130145 creator A5028960653 @default.
• W4211130145 creator A5029468973 @default.
• W4211130145 creator A5031125097 @default.
• W4211130145 creator A5031833848 @default.
• W4211130145 creator A5032207933 @default.
• W4211130145 creator A5032822928 @default.
• W4211130145 creator A5033341769 @default.
• W4211130145 creator A5033346393 @default.
• W4211130145 creator A5035148842 @default.
• W4211130145 creator A5036063976 @default.
• W4211130145 creator A5036552481 @default.
• W4211130145 creator A5036810515 @default.
• W4211130145 creator A5039006271 @default.
• W4211130145 creator A5039157590 @default.
• W4211130145 creator A5040049242 @default.
• W4211130145 creator A5040091505 @default.
• W4211130145 creator A5040632988 @default.
• W4211130145 creator A5042977437 @default.
• W4211130145 creator A5044836497 @default.
• W4211130145 creator A5047119964 @default.
• W4211130145 creator A5047662950 @default.
• W4211130145 creator A5048616139 @default.
• W4211130145 creator A5049339555 @default.
• W4211130145 creator A5049675726 @default.
• W4211130145 creator A5053712453 @default.
• W4211130145 creator A5053984949 @default.
• W4211130145 creator A5054152805 @default.
• W4211130145 creator A5055056020 @default.
• W4211130145 creator A5055241360 @default.
• W4211130145 creator A5055961498 @default.
• W4211130145 creator A5056237086 @default.
• W4211130145 creator A5056253977 @default.
• W4211130145 creator A5057083170 @default.
• W4211130145 creator A5058350984 @default.
• W4211130145 creator A5058981955 @default.
• W4211130145 creator A5059092900 @default.
• W4211130145 creator A5062201991 @default.
• W4211130145 creator A5062439911 @default.
• W4211130145 creator A5063804548 @default.
• W4211130145 creator A5066665869 @default.
• W4211130145 creator A5067351502 @default.
• W4211130145 creator A5067403767 @default.
• W4211130145 creator A5070251617 @default.
• W4211130145 creator A5071211289 @default.
• W4211130145 creator A5071853895 @default.
• W4211130145 creator A5075012039 @default.
• W4211130145 creator A5076723423 @default.
• W4211130145 creator A5078012266 @default.
• W4211130145 creator A5078426399 @default.
• W4211130145 creator A5079283894 @default.
• W4211130145 creator A5079518105 @default.
• W4211130145 creator A5079598587 @default.
• W4211130145 creator A5080024971 @default.
• W4211130145 creator A5082515914 @default.
• W4211130145 creator A5083387295 @default.
• W4211130145 creator A5084817085 @default.
• W4211130145 creator A5085376424 @default.
• W4211130145 creator A5087667216 @default.
• W4211130145 creator A5088692015 @default.
• W4211130145 creator A5088796813 @default.
• W4211130145 creator A5089088109 @default.
• W4211130145 creator A5089270473 @default.
• W4211130145 creator A5090954044 @default.
• W4211130145 date "2022-03-01" @default.
• W4211130145 modified "2023-10-01" @default.
• W4211130145 title "Editor's Choice – Randomised Clinical Trial of Supervised Exercise Therapy vs. Endovascular Revascularisation for Intermittent Claudication Caused by Iliac Artery Obstruction: The SUPER study" @default.

• next